In a unanimous decision, an appellate court has resoundingly rejected the legal claim that sovereign immunity, as argued by a Native American tribe, can act as a shield for a patent review process.
By Shares of Acorda Therapeutics Inc. tumbled more than 17% Wednesday, after the company said an appeals court has denied its motion on patents for its multiple sclerosis treatment Ampyra. The company had filed for an injunction pending a decision in its appeal of a U.S.
BENGALURU: Engineering students of various colleges have been coming up with remarkable innovations through their college projects. Some have even impressed private sector firms and also defence sector units, who have adopted at least parts of those technologies in their units. But, at the students’ level, those innovations are lost after they graduate from the colleges.
The patent troll narrative has dominated our cultural consciousness ever since a clever Intel lawyer coined the term in the early 2000s. Even if you know nothing about patents, you’re probably familiar with the concept. Companies with no intention of producing anything buy up overly broad patents to extort other businesses with.
BENGALURU: The number of patents filed by a US firm in India in 2016-17 was more than double of all patent applications from 50 labs under DRDO, more than 40 labs in IISc, 38 labs under CSIR, 31 NITs, 23 IITs and six major research facilities under Isro.
Your usage has been flagged as a violation of our terms of service. For inquiries related to this message please contact support. For sales inquiries, please visit http://www.bloomberg.com/professional/request-demo
Apple Inc, Oath Inc and Alphabet Inc’s Google on Friday won a ruling from a federal appeals court invalidating claims in a “pop up” computer notification patent they were accused of infringing.
The Centre has taken steps to analyse the performance of Atal Incubation Centres, which incubates start-ups. This performance monitoring will happen through an online medium. For this purpose, a pl
Principe and Rudroff unfortunately regurgitate much of the misguided dialogue, which has done nothing to serve this country except to decimate its patent system in recent years. It is worth noting the conclusions reached are not supported by even an FTC study commissioned for the purpose of condemning patent trolls.
After TCL lost its IPRs against Ericsson in a written decision at PTAB, it was barred from filing subsequent IPRs against the ‘510 patent. TCL was then hit with a very large verdict. Four months after the verdict the same patent is challenged at the PTAB again by a consortium that has some relationships to TCL.
The Federal Circuit has prevented a private company from using a Native American tribe’s rights to bar the Patent Office from reviewing its patents. The case involves a pharmaceutical company, Allergan, that paid the Saint Regis Mohawk Tribe to “own” its patents, and then assert sovereign immunity…
The strategy was breathtaking in its boldness. Just days before the USPTO was to hear a challenge to Allergan Inc.’s patents on a dry-eye drug, Restasis, the company transferred those patents to a Native American tribe; the tribe then sought to dismiss the USPTO proceedings by asserting sovereign immunity.
Federal Circuit rules tribal sovereign immunity cannot be asserted in IPRs – IPWatchdog.com | Patents & Patent Law
Federal Circuit, in an opinion authored by Judge Moore, affirmed the determination of the PTAB affirmed the decision of the PTAB, holding that tribal sovereign immunity cannot be asserted in IPRs. There can be little doubt, this case is headed for the Supreme Court.
Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to extend that win to the legal system, hoping to block copycats from entering the U.S. until 2027.
Oppositions Filed Against Gilead Hepatitis C Patent Applications In India – Intellectual Property Watch
Oppositions have been filed in India against two patent applications from US pharmaceutical company Gilead for important hepatitis C medicines, according to non-governmental sources. The opposition filings assert that these applications are “evergreening” patents and therefore violate Indian patent law.